Landiolol

Evidence Level: L5

Predicted Indications: 6

Landiolol

Pharmacist Assessment Report

Landiolol: From Supraventricular Tachycardia to Lingual-Facial-Buccal Dyskinesia

One-Sentence Summary

Landiolol is an ultra-short-acting, highly beta-1-selective adrenergic blocker given intravenously in critical care for supraventricular tachycardia (atrial fibrillation and atrial flutter). The TxGNN model predicts it may be effective for lingual-facial-buccal dyskinesia, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.

Quick Overview

Item	Content
Original Indication	Supraventricular tachycardia (atrial fibrillation and atrial flutter), based on pharmacology reference data; the Canadian licence record has no indication text
Predicted New Indication	Lingual-facial-buccal dyskinesia
TxGNN Prediction Score	0.9911
Evidence Level	L5
Canada Market Status	Approved but not marketed (approvals on record: 1)
Number of DINs	1 (marketed: 0)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Pharmacology reference data show that landiolol binds the beta-1 adrenoceptor with about 250-fold selectivity over the beta-2 adrenoceptor. It is given intravenously for short-term control of heart rate in acute care.

The link to the predicted indication is weak. Beta-blockers, mainly the non-selective and brain-penetrant propranolol, have been used for some hyperkinetic movement disorders such as tremor and akathisia. There is no established link between beta-1-selective blockade and orofacial dyskinesia. Landiolol is hydrophilic and crosses the blood-brain barrier poorly, so central effects are unlikely.

The TxGNN score is high (0.9911), but it comes from a network-based prediction. It does not replace mechanistic or clinical evidence, and the mechanism cannot be verified with the current data.

Other predictions in the same list (all L5, all Hold, no trials or literature):

Predicted Indication	TxGNN Score	Comment
Chronic tic disorder	0.9908	Usually managed with alpha-2 agonists and antipsychotics; an IV ultra-short-acting drug is a poor fit for a chronic condition
Psychogenic movement disorders	0.9905	No clear pharmacological rationale; treated mainly with rehabilitation and psychotherapy
Extrapyramidal and movement disease	0.9904	Category too broad to support a mechanistic claim
Benign shuddering attacks	0.9904	Rare, self-limiting condition that usually needs no drug treatment
Primary orthostatic tremor	0.9900	Beta-blockers are generally ineffective; clonazepam, gabapentin, or primidone are typically used

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02543338	SIBBORAN	Not specified	Not specified

Safety Considerations

Pharmacological profile: Landiolol acts on the beta-1 adrenoceptor (ADRB1) and, to a much lesser degree, the beta-2 adrenoceptor (ADRB2). It is given intravenously in a critical care setting. No specific drug-drug interactions are recorded in the data compiled for this report. The two entries are the drug’s pharmacological targets, not interacting drugs.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone. There are no clinical trials or publications, and the mechanism is unverified. Landiolol’s pharmacology (beta-1 selective, hydrophilic, intravenous, ultra-short-acting) fits poorly with chronic or central movement disorders.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications, which block safety screening
Mechanism of action data, to assess any link between beta-1 blockade and movement disorders
Original indication text from the Canadian licence
A literature and trial search for beta-blockers in dyskinesia and related movement disorders
A route-of-administration compatibility assessment, since landiolol is available only as an IV formulation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.